ExpressPoints: Current and Emerging Clinical Strategies for Pancreatic Cancer Treatment

Download this short summary slideset of key takeaway points on treating patients with pancreatic cancer, including those with resectable and unresectable disease with or with actionable mutations.
Michael J. Pishvaian, MD, PhD
Rachna Shroff, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 782 KB
Released: January 28, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Ipsen Biopharmaceuticals, Inc.

Related Content

Module from Clinical Care Options (CCO): Christine Chio, PharmD, BCOP; Lipika Goyal, MD; and Caroline Kuhlman, NP, discuss current treatment of cholangiocarcinoma, including the use of biomarkers

Christine Chio, PharmD, BCOP Lipika Goyal, MD Caroline Kuhlman, NP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 13, 2022 Expired: May 12, 2023

Review this slideset on the current treatment of cholangiocarcinoma with expert perspectives from Christine Chio, PharmD, BCOP; Lipika Goyal, MD; and Caroline Kuhlman, NP.

Christine Chio, PharmD, BCOP Lipika Goyal, MD Caroline Kuhlman, NP Released: May 13, 2022

On-demand webcast on HER2, HER3, and TROP2 antibody-drug conjugates in breast, gastrointestinal, and lung cancers, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Yelena Y. Janjigian, MD Sandip P. Patel, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: May 11, 2022 Expired: May 10, 2023

From Clinical Care Options (CCO), downloadable PDF featuring key points from expert discussion on PARP inhibitors in treatment of pancreatic cancer

Eileen M. O'Reilly, MD person default Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP Released: May 3, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings